Bristol-Myers Squibb Co
CELG_r0.030USD
0.000
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Bristol-Myers Squibb Co Compañía
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Información de la empresa
Símbolo de cotizaciónCELG_r
Nombre de la empresaBristol-Myers Squibb Co
Fecha de salida a bolsaMar 17, 1980
Director ejecutivoDr. Christopher S. (Chris) Boerner, Ph.D.
Número de empleados- -
Tipo de seguridad- -
Fin del año fiscal- -
DirecciónRoute 206 And Province Line Road
CiudadPRINCETON
Bolsa de valores- -
PaísUnited States of America
Código postal08543
Teléfono16092524621
Sitio Webhttps://www.bms.com
Símbolo de cotizaciónCELG_r
Fecha de salida a bolsaMar 17, 1980
Director ejecutivoDr. Christopher S. (Chris) Boerner, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael R. (Mike) Mcmullen
Mr. Michael R. (Mike) Mcmullen
Independent Director
Independent Director
--
--
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. Greg Scott Meyers
Mr. Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
--
--
Ms. Amanda Poole
Ms. Amanda Poole
Executive Vice President, Chief People Officer, Member of the Leadership Team
Executive Vice President, Chief People Officer, Member of the Leadership Team
--
--
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert Plenge, M.D., Ph.D.
Mr. Robert Plenge, M.D., Ph.D.
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team
--
--
Dr. Karen H. Vousden, Ph.D.
Dr. Karen H. Vousden, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael R. (Mike) Mcmullen
Mr. Michael R. (Mike) Mcmullen
Independent Director
Independent Director
--
--
Mr. Benjamin Hickey
Mr. Benjamin Hickey
President - RayzeBio Organization, Member of the Leadership Team
President - RayzeBio Organization, Member of the Leadership Team
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Ms. Phyllis R. Yale
Ms. Phyllis R. Yale
Independent Director
Independent Director
--
--
Mr. Greg Scott Meyers
Mr. Greg Scott Meyers
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 30 de jul
Actualizado: mié., 30 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Other
100.00%
Accionistas
Accionistas
Proporción
Other
100.00%
Tipos de accionistas
Accionistas
Proporción
Other
100.00%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
33
482.65K
0.00%
-636.67K
2025Q1
32
482.82K
0.00%
-636.30K
2024Q4
32
943.43K
0.00%
+289.58K
2024Q3
31
601.53K
0.00%
-30.97K
2024Q2
30
511.50K
0.00%
+7.21K
2024Q1
32
397.74K
0.00%
-298.70K
2023Q4
30
495.62K
0.00%
-151.97K
2023Q3
30
535.93K
0.00%
-247.50K
2023Q2
31
542.98K
0.00%
-138.59K
2023Q1
34
441.11K
0.00%
-360.09K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Transcend Capital Advisors, LLC
109.17K
0%
-8.60K
-7.30%
Mar 31, 2025
Davenport Asset Management
83.97K
0%
--
--
Mar 31, 2025
Maven Investment Partners US Ltd.
67.86K
0%
--
--
Mar 31, 2025
BofA Global Research (US)
51.82K
0%
+180.00
+0.35%
Mar 31, 2025
Purkiss Capital Advisors LLC
26.45K
0%
--
--
Mar 31, 2025
Two Sigma Investments, LP
25.68K
0%
-465.00
-1.78%
Mar 31, 2025
MainStreet Advisors
20.00K
0%
--
--
Mar 31, 2025
Watts Gwilliam & Co LLC
20.00K
0%
--
--
Mar 31, 2025
Private Advisor Group LLC
15.00K
0%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
